HAEMONETICS CORP — Director's Dealing 2019

Jun 10, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2019-06-06

Reporting Person: Basil Michelle L (EVP and General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-06	Common Stock	M	6148	$41.64	Acquired	21832	Direct
2019-06-06	Common Stock	S	6148	$103.25	Disposed	15684	Direct
2019-06-07	Common Stock	M	4872	$38.43	Acquired	20556	Direct
2019-06-07	Common Stock	S	6745	$103.50	Disposed	13811	Direct
2019-06-07	Common Stock	S	442	$103.38	Disposed	13369	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-06	Non-qualified Stock Option (Right to Buy)	$41.64	M	6148	Disposed	2024-06-06	Common Stock (6148)	Direct
2019-06-07	Non-qualified Stock Option (Right to Buy)	$38.43	M	4872	Disposed	2024-03-06	Common Stock (4872)	Direct

Footnotes

F1: Transaction pursuant to an existing 10b5-1 trading plan.

F2: This number includes unvested RSUs previously reported.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F4: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.